Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rosa De Abreu Ferreira"'
Autor:
Paul Rizzoli, Michael J. Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J. Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H. Smith, Brett Dabruzzo, Messoud Ashina
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated preventive treatments are needed to reduce migraine sym
Externí odkaz:
https://doaj.org/article/04ca5a47ea8141e181232ded6eeb22d4
Autor:
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic as
Externí odkaz:
https://doaj.org/article/1ec46728fbc04f62a659f561489d4b07
Autor:
Andrew M, Blumenfeld, Ramesh, Boinpally, Rosa, De Abreu Ferreira, Joel M, Trugman, Brett, Dabruzzo, Jessica, Ailani, Richard B, Lipton
Publikováno v:
Headache: The Journal of Head and Face Pain. 63:322-332
To evaluate potential drug-drug interactions of ubrogepant and atogepant.Ubrogepant and atogepant, calcitonin gene-related peptide (CGRP) receptor antagonists, are recently approved drugs for acute and preventive treatment of migraine, respectively.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::549e1809f1125ec77357581c11ef064c
https://doi.org/10.1111/head.14433
https://doi.org/10.1111/head.14433
Autor:
Patricia Best, Andrea Harriott, Teshamae Monteith, Cristina Tassorelli, Stephanie Nahas, Yingyi Liu, Brett Dabruzzo, Rosa De Abreu Ferreira, Jonathan H. Smith
Publikováno v:
Wednesday, April 26.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dec14aae414b78d7a761397d8a8bd15
https://doi.org/10.1212/wnl.0000000000202040
https://doi.org/10.1212/wnl.0000000000202040
Autor:
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Publikováno v:
Pharmacology Research & Perspectives. 11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::845510e3de7301902bc2085045e754f2
https://doi.org/10.1002/prp2.1036
https://doi.org/10.1002/prp2.1036
Autor:
Mohamad, Shebley, Stanley, Wang, Izna, Ali, Preethi, Krishnan, Rakesh, Tripathi, Joseph M, Reardon, John, Cafardi, Galia, Rahav, Yoseph, Caraco, Jihad, Slim, Fadi, Al Akhrass, Mengjia, Yu, Yiran, Hu, Rosa De Abreu, Ferreira, Negar N, Alami
Publikováno v:
Pharmacology researchperspectivesREFERENCES. 11(1)
ABBV-47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS-CoV-2. This first-in-human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7efe048bc5e78f8b29de9295f93365ad
https://pubmed.ncbi.nlm.nih.gov/36537346
https://pubmed.ncbi.nlm.nih.gov/36537346